• Therapeutically targeting endothelial cell metabolic dysfunction in pulmonary arterial hypertension with apigenin, Iona Cuthbertson
• Epigenome-wide profiling uncovers novel gene regulatory networks in human pulmonary arterial hypertension, Prakash Chelladurai
• Implication of the histone methyltransferase “g9a” in pulmonary arterial hypertension, Charifa Awada 
• Perinatal exposure to serotonin re-uptake inhibitor causes mild pulmonary hypertension in adult female rats, Barbora Kaftanová 
• Endothelial overexpression of sirt3 protects the metabolic etiology in PAH, Anandharajan Rathinasabapath
• Axl is a novel modulator of bone morphogenetic protein receptor 2 in pulmonary arterial hypertension, Tatyana Novoyatleva 
• Equivalent outcomes for hereditary and idiopathic pulmonary arterial hypertension in children; an analysis from a national Australian registry, Katherine Kearney Graham 
• Effect of macitentan across prognostic age groups in patients with pulmonary arterial hypertension (PAH), Richard Channick
• Validation of artificial intelligence artery-vein Classification for Contrast CT imaging in PH subjects, Pietro Nardelli
• Efficacy in patient subgroups in the INCREASE Trial, a phase III Trial to evaluate inhaled Treprostinil in patients with pulmonary hypertension due to parenchymal Lung Disease, Victor Tapson
• Acetazolamide and high altitude pulmonary edema prevention, Erik Swenson 
• Telomeric Tankyrases: a novel and propitious target to ameliorate the maladaptation phenomena at heights, Manjula Miglani 

It has become increasingly clear in the last two decades, thanks to epidemiological studies and clinical trials, that Group 3 pulmonary hypertension is in fact a constellation of different and varied phenotypes.

Reports documenting the presence and impact of pulmonary hypertension (PH) complicating lung disease date back to the early 1980s. Ever since effective therapies for group 1 pulmonary arterial hypertension started to emerge in the 1990s with IV epoprostenol, through the early 2000s with the endothelin receptor antagonists and PDE-5 inhibitors, there has been increasing interest in the potential role of these therapies for PH beyond group 1 disease (1)...

• SARS-1, MERS, SARS-2 and more: are coronavirus infections an ubiquitous part of our lives? Albert Osterhaus
• Endothelitis and aberrant angiogenesis – mechanisms of COVID-19 induced vascular injury, Danny Jonigk
• Venous thromboembolism in COVID-19: Prevalence and clinical picture, Stavros Konstantinides
• ACE-II receptors – Modulation of PVD in COVID-19? Anna Hemnes
• Tricuspid regurgitation, as proxy for acute pulmonary hypertension, and its association with short-term outcome in severe Covid-19, Claes Frostell 
• Venous and arterial thromboembolism in COVID-19: a systematic review with meta-analysis, Vicky Mai

• Health and wearables: Is this the dawn of a new age for cardiovascular medicine? Martin Cowie
• Professor Sheila Glennis Haworth Memorial Lecture - Translational Research on PAH, Jason Yuan 
• Biomarker Analysis of the PULSAR Study: An Ongoing Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of PAH, Marc Humbert
• Switching from PDE5i to riociguat in patients with PAH: The REPLACE study, Raymond Benza
• A diagnostic miRNA signature for PAH using a consensus machine learning approach (Rupert Swift Award 2021), Niamh Errington

• The view of the World Heart Federation (WHF), Fausto Pinto
• Update on the Global Burden of PH Project of the Institute for Health Metrics and Evaluation (IHME), Sophia Emmons-Bell
• PVRI GoDeep: Perspectives of a global meta-registry, Werner Seeger
• Mortality of idiopathic/hereditary and connective tissue disease-associated pulmonary arterial hypertension: the data from first single center prospective registry in Indonesia, Anggoro Budi Hartopo
• Triple therapy in pulmonary arterial hypertension in an expert centre in Mexico City. Real-life results, Humberto Garcia-Aguilar